US EditionPublished • loading... • Updated
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma
Summary by Mid Florida Newspapers
1 Articles
1 Articles
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma
JUPITER, Fla., Oct. 22, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
